Cosentyx (secukinumab) - Novartis
Cosentyx: Completion of P3 trial (NCT03031782) for psoriatic arthritis in 2021 (Novartis) - Oct 22, 2019 - Q3 2019 Results 
Trial completion date
https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf
 
Oct 22, 2019
 
 
708e43da-107c-40c8-ac34-1f4cb78ec9c6.jpg